SCHEMBL25327296

SCHEMBL25327296

CCOC(=O)c1c(C)nc(-c2cccc(-c3nnn[nH]3)c2)n1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F11 P03951 2/20 0.42
ALDH1A1 P00352 5/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 6/20 0.41
MAPT P10636 6/20 0.41
RAB9A P51151 4/20 0.41
KDM4E B2RXH2 3/20 0.41
CYP1A2 P05177 2/20 0.41
MAPK1 P28482 3/20 0.40
GLA P06280 1/20 0.38
NPC1 O15118 2/20 0.38
KMT2A Q03164 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HCRTR1 O43613 1/20 0.37
TP53 P04637 1/20 0.37
ALOX15 P16050 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30638337 1.00 F11 (0.42) F11ALDH1A1PKMSMN1; SMN2MAPT
SCHEMBL26108969 0.85 F11 (0.57) F11ALDH1A1PKMMAPTCYP1A2
SCHEMBL5639017 0.81 NPC1 (0.49) ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E
SCHEMBL25327230 0.79 ALDH1A1 (0.42) F11ALDH1A1PKMSMN1; SMN2MAPT
SCHEMBL29565728 0.78 TRPM8 (0.53) F11ALDH1A1PKMSMN1; SMN2MAPT
SCHEMBL28746466 0.78 TRPM8 (0.53) F11ALDH1A1PKMSMN1; SMN2MAPT
SCHEMBL25328154 0.78 CYP1A2 (0.66) ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E
SCHEMBL25325875 0.76 F11 (0.72) F11ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL29151908 0.73 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E
SCHEMBL30019463 0.73 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114105881-B Platelet aggregation inhibitor, and preparation method and application thereof 沈阳海诺威医药科技有限公司 2024-01-26 CN claimed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP claimed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US claimed
CN-114105881-B Platelet aggregation inhibitor, and preparation method and application thereof 沈阳海诺威医药科技有限公司 2024-01-26 CN disclosed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP disclosed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof TFPI, F12, TFPI2 F11 7/4885ALDH1A1 1546/4885PKM 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.